AI Insight
Two new studies published in PLOS Biology investigate the problem of poorly validated antibodies in scientific research, which leads to misleading experimental results and wastes valuable research resources. The studies quantify the ethical and financial costs associated with using unvalidated antibodies, explore the reasons researchers continue to use them despite known validation issues, and propose practical solutions to reduce their prevalence in scientific studies.
Why it matters
Unvalidated antibodies compromise the reliability and reproducibility of scientific research, potentially leading to false conclusions that can misdirect future studies and clinical applications. Addressing this issue could significantly improve research quality, reduce wasted funding, and accelerate scientific progress across multiple fields that depend on antibody-based techniques.
Understand the Science
by Johan Duchêne
Poorly validated antibodies generate misleading results and waste research resources. Two new studies in PLOS Biology quantify the ethical costs of this issue, examine why unvalidated antibodies are still used, and identify solutions to reduce their use.
Poorly validated antibodies generate misleading results and waste research resources. This Primer explores two new studies in PLOS Biology that quantify the ethical costs of this issue, examine why unvalidated antibodies are still used, and identify solutions to reduce their use.